Ownership and insider activity for Eton Pharmaceuticals, Inc. (ETON): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and...
Price
| Price | $56.35 |
| Market Cap | $1.5B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-08-28 | MAIER PAUL V | M-Exempt | 12,500 | $91K |
| 2026-08-28 | MAIER PAUL V | M-Exempt | 12,500 | $91K |
| 2026-08-28 | MAIER PAUL V | M-Exempt | 50,000 | $189K |
| 2026-08-28 | MAIER PAUL V | S-Sale | 36,387 | $2.1M |
| 2026-08-28 | MAIER PAUL V | S-Sale | 13,485 | $812K |
| 2026-08-28 | MAIER PAUL V | S-Sale | 128 | $8K |
| 2026-08-28 | MAIER PAUL V | M-Exempt | 50,000 | $189K |
| 2026-08-24 | Krempa David | M-Exempt | 25,000 | $183K |
| 2026-08-24 | Krempa David | M-Exempt | 25,000 | $183K |
| 2026-08-24 | Krempa David | S-Sale | 25,000 | $1.6M |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.2M | $26.7M | $12.1M | $21.3M | $14.4M | $16.3M | $21.4M | $14.9M | $25.9M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | $473000 | $48000 | $5.5M | $1.9M | $3.4M | $5.4M | $11.8M |
| Inventory | 0 | 0 | $380000 | $1.2M | $550000 | $557000 | $911000 | $15.2M | $15.4M |
| Total Current Assets | $13.3M | $27.5M | $15.0M | $24.7M | $23.6M | $20.0M | $26.8M | $41.0M | $60.6M |
| Property, Plant & Equipment | $119000 | $773000 | $1.3M | $1.0M | $219000 | $260000 | $150000 | $209000 | $636000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | $725000 | $575000 | $3.6M | $4.8M | $4.7M | $34.9M | $30.9M |
| Total Assets | $13.4M | $28.3M | $17.1M | $26.3M | $27.5M | $25.0M | $31.7M | $76.1M | $92.1M |
| Accounts Payable | $539000 | $1.4M | $575000 | $2.3M | $1.8M | $1.8M | $1.8M | $4.2M | $11.0M |
| Short-term Debt | 0 | 0 | 0 | $280000 | $1.4M | $1.0M | $5.4M | $76000 | $8.8M |
| Total Current Liabilities | $793000 | $2.0M | $2.0M | $3.8M | $4.6M | $6.5M | $16.2M | $19.9M | $38.5M |
| Long-term Debt | 0 | 0 | $4.5M | $6.8M | $5.3M | $5.4M | 0 | $29.8M | $21.8M |
| Total Liabilities | $1.3M | $2.0M | $6.5M | $10.7M | $9.8M | $12.0M | $16.3M | $51.7M | $66.0M |
| Retained Earnings | -$8.6M | -$45.9M | -$64.2M | -$92.2M | -$94.1M | -$103.1M | -$104.1M | -$107.9M | -$112.5M |
| Total Equity | $12.1M | $26.3M | $10.6M | $15.7M | $17.6M | $13.1M | $15.5M | $24.4M | $26.2M |
| Total Debt | 0 | 0 | $4.6M | $7.1M | $6.7M | $6.5M | $5.4M | $30.0M | $31.0M |
| Net Debt | -$13.2M | -$26.7M | -$7.5M | -$14.2M | -$7.7M | -$9.8M | -$16.0M | $15.1M | $5.1M |
| Working Capital | $12.5M | $25.5M | $13.0M | $20.9M | $19.0M | $13.5M | $10.6M | $21.1M | $22.1M |
Financial Health
| Debt / Equity | 0.62 |
| Current Ratio | 1.52 |
Profitability
| Return on Equity | 40.13% |
| Return on Invested Capital | 20.41% |
| Return on Assets | 10.96% |
| Gross Margin | 57.87% |
| Operating Margin | 15.44% |
| Net Margin | 12.02% |
Related companies: ADCT · BCYC · FULC · LCTX · LXRX · MNPR · NMRA
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of ETON: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks